Acme United Corporation
ACUAcme United Corporation's price has outrun its earnings. +38.9% in a year against EPS +1.6% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +38.9% in a year while annual EPS moved +1.6% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is between stages while the P/E sits at the 96th percentile of its own 1-year range. Underneath, the last four quarters read mixed, and 150% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Acme United Corporation trades at $55.8, between stages. That is +29.4% against its own 200-day average. It sits at 94% of a 52-week range of $37 to $57. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 3 straight weeks.
Today the stock is between stages. At $55.8 it trades +29.4% versus its 200-day average and sits at 94% of its 52-week range ($37–$57).
Against the market, two honest reads. Cumulative: over the last 1.1 years the stock moved +30% while the S&P 500 moved +24% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 3 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Acme United Corporation trades at 23.4× P/E, at the pricey end of its own range (96th percentile). Its long-run median P/E is 17.4×, measured across 1.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 23.4× is at the pricey end of its own range (96th percentile), against a long-run median of 17.4× measured over 1.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +1.6% against a +38.9% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Acme United Corporation reads as deteriorating on its fundamental arc. Deteriorating — revenue and EPS growth are shrinking (revenue growth −4.8% latest against +16.7% at its 12-quarter best), ROCE holding at 6.2%. The read is built from 12 quarters across 3 curves, on partial evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +5.3% | +1.7% | — | — |
| Profit | +0.0% | — | — | — |
| EPS | +1.6% | +44.8% | — | — |
| Stock price | +38.9% | — | — | — |
4-Factor Sector Score
43.6/100 — rank 12 of 20 in Household & Personal Products · 75% evidence confidence
Acme United Corporation scores 43.6 out of 100 against the 20 companies it is compared with in Household & Personal Products, ranking 12. Price leads the evidence: RS versus the benchmark is 16.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 13.9 + 9.1 + 6 + 14.6 = 43.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Acme United Corporation reported $0.1 B of revenue in the Mar 26 quarter, +0.0% year on year. Over 4 years it has compounded at 2.7% a year. The last full year, FY25, came in at $0.2 B. The last four reported quarters add to $0.2 B.
FY25 revenue came in at $0.2 B (+5.3% on the year), capping 4 years at 2.7% compound. The latest quarter (Mar 26) printed $0.1 B, +0.0% year on year.
Pace check: the last four quarters averaged −4.2% growth against the decade's 2.7% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −4.8% over the last 4 quarters against +5.4%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Acme United Corporation's operating margin is 0.0% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 5.0% to 5.6%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 0.0%, +0.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 5.0%–5.6%.
Why the margin moved: operating margin went +0.0 pp year on year while gross margin went +0.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Acme United Corporation earned $0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. The 4-year compound rate is 0.0%. That is 0.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B.
Mar 26 profit was $0.0 B, null year on year. On the full year, FY25 printed $0.0 B (+0.0%), and the 4-year compound rate is 0.0%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 150% of Acme United Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.0 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $0.0 B was left as free cash.
FY25: operating cash of $0.0 B against reported profit of $0.0 B, leaving free cash of $0.0 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 150% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Acme United Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Acme United Corporation earns a ROE of 8% in FY25. That is up from a trough of 0% in FY22. Return on invested capital clears the cost of that capital by +0.7 percentage points, so growth here adds value rather than only size. The wiring behind it is 5.0% net margin on 1.18× asset turns.
FY25 ROE is 8%, recovered from a FY22 trough of 0% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 5.0% net margin × 1.18× asset turns × 1.42× balance-sheet leverage ≈ 8.4% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 7.2% − 6.5% = a +0.7 pp spread. The 6.5% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Acme United Corporation paid $0.64 per share over the last four reported quarters, up 6.7% on a year ago. The most recent declaration was $0.16 for Mar 26. Against the current price of $55.8 that is a trailing yield of 1.15%, measured on dividends already paid rather than on a forecast.
Acme United Corporation paid $0.64 per share across the last four reported quarters, most recently $0.16 for Mar 26. That is up 6.7% against the same quarter a year earlier. Against the current price of $55.8 the trailing twelve months work out to 1.15% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Acme United Corporation carries total debt of $0.1 B against shareholder equity of $0.1 B as of Mar 26, a debt-to-equity of 0.42. On the annual view that ratio went from 0.63 in FY21 to 0.25 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $0.1 B against shareholder equity of $0.1 B — a debt-to-equity of 0.42. On the annual view, debt-to-equity went from 0.63 (FY21) to 0.25 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
3.2% of Acme United Corporation's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 5.3 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 3.2% of the float is sold short, and at typical trading volumes it would take about 5.3 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Acme United Corporation: the Z-score reads 3.70. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.70 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.70.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Helen of Troy LimitedHELE | 67.6/100Favorable setup71% evidence | LEADER | 24.3/35 Revenue -2.5% · PAT 100% · OPM change 124.5 pp 71% evidence | 12.4/25 ROCE 3.2% · OPM 15% 76% evidence | 15.8/20 P/E 10.2× · PEG 0.42 65% evidence | 15.1/20 RS sector 16.7% · RS bench 16.7% · 1Y 29.5%12 of 12 weeks ahead 70% evidence |
| Exact sum: 24.3 + 12.4 + 15.8 + 15.1 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Kenvue Inc.KVUE | 63.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 24.5/35 Revenue -0.1% · PAT 53.6% · OPM change 4.7 pp 83% evidence | 15.0/25 ROCE 3.8% · OPM 19.6% 76% evidence | 14.9/20 P/E 20.6× · PEG 0.38 65% evidence | 9.5/20 RS sector -1.5% · RS bench -1.6% · 1Y -8.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 15 + 14.9 + 9.5 = 63.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Interparfums, Inc.IPAR | 59.8/100Mixed-positive evidence81% evidence | BREAKING OUT | 15.6/35 Revenue 1.8% · PAT 1.5% · OPM change -0.7 pp 83% evidence | 15.8/25 ROCE 6.3% · OPM 21.5% 76% evidence | 9.9/20 P/E 17.2× · PEG 1.99 65% evidence | 18.5/20 RS sector 17.8% · RS bench 17.4% · 1Y 11%6 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 15.8 + 9.9 + 18.5 = 59.8 · Decision use: Price leads the evidence: RS versus the benchmark is 17.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 4Newell Brands Inc.NWL | 56.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 19.1/35 Revenue — · PAT — · OPM change 0.9 pp 45% evidence | 8.4/25 ROCE 3.3% · OPM 2.2% 76% evidence | 9.6/20 P/E 27.8× · PEG — 15% evidence | 19.4/20 RS sector 22.9% · RS bench 21.7% · 1Y 25.6%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 8.4 + 9.6 + 19.4 = 56.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5The Clorox CompanyCLX | 54.4/100Mixed-positive evidence81% evidence | TURNING | 21.1/35 Revenue -3.7% · PAT 8.6% · OPM change 2.7 pp 83% evidence | 15.3/25 ROCE 8.7% · OPM 17.3% 76% evidence | 11.9/20 P/E 16.8× · PEG 1.59 65% evidence | 6.1/20 RS sector -12.3% · RS bench -12.9% · 1Y -16.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 15.3 + 11.9 + 6.1 = 54.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Spectrum Brands Holdings, Inc.SPB | 52.0/100Mixed-positive evidence81% evidence | TURNING | 21.5/35 Revenue -3.7% · PAT 100% · OPM change 3.2 pp 83% evidence | 8.2/25 ROCE 1.5% · OPM 6.1% 76% evidence | 9.6/20 P/E 14× · PEG 2.17 65% evidence | 12.7/20 RS sector 16.8% · RS bench 17.9% · 1Y 61.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 8.2 + 9.6 + 12.7 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Kimberly-Clark CorporationKMB | 51.7/100Mixed-positive evidence81% evidence | BREAKING OUT | 19.5/35 Revenue 0.1% · PAT -18.8% · OPM change 2.5 pp 83% evidence | 16.3/25 ROCE 7.7% · OPM 18.1% 76% evidence | 8.1/20 P/E 15.1× · PEG 2.35 65% evidence | 7.8/20 RS sector -7.1% · RS bench -7.7% · 1Y -18.1%4 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 16.3 + 8.1 + 7.8 = 51.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Magnera CorporationMAGN | 50.0/100Thin evidence · provisional58% evidence | BREAKING OUT | 20.7/35 Revenue 35.3% · PAT — · OPM change 1.6 pp 62% evidence | 5.7/25 ROCE 0.5% · OPM 2.1% 76% evidence | 11.2/20 P/E 12.2× · PEG — 15% evidence | 12.4/20 RS sector 2.6% · RS bench 2.3% · 1Y 7.7%8 of 12 weeks ahead 70% evidence |
| Exact sum: 20.7 + 5.7 + 11.2 + 12.4 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Church & Dwight Co., Inc.CHD | 49.3/100Thin evidence · provisional58% evidence | TURNING | 17.7/35 Revenue — · PAT — · OPM change -0.3 pp 45% evidence | 13.6/25 ROCE 3.6% · OPM 19.8% 76% evidence | 9.4/20 P/E 31.2× · PEG — 15% evidence | 8.6/20 RS sector -0.9% · RS bench -0.8% · 1Y 13.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 13.6 + 9.4 + 8.6 = 49.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Colgate-Palmolive CompanyCL | 47.3/100Thin evidence · provisional58% evidence | TURNING | 15.2/35 Revenue — · PAT — · OPM change -3.8 pp 45% evidence | 16.7/25 ROCE 9.5% · OPM 18.1% 76% evidence | 9.3/20 P/E 36.4× · PEG — 15% evidence | 6.1/20 RS sector -3.3% · RS bench -3.1% · 1Y 9.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 16.7 + 9.3 + 6.1 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11The Procter & Gamble CompanyPG | 45.5/100Thin evidence · provisional58% evidence | BASING | 16.7/35 Revenue — · PAT — · OPM change -1.5 pp 45% evidence | 15.8/25 ROCE 4.5% · OPM 21.5% 76% evidence | 9.8/20 P/E 22.2× · PEG — 15% evidence | 3.2/20 RS sector -11.2% · RS bench -11.4% · 1Y -3.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 15.8 + 9.8 + 3.2 = 45.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Acme United Corporationthis pageACU | 43.6/100Mixed-negative evidence75% evidence | TURNING | 13.9/35 Revenue 4.1% · PAT 0% · OPM change -2 pp 83% evidence | 9.1/25 ROCE 1.1% · OPM 3.3% 76% evidence | 6.0/20 P/E 19.4× · PEG 2.81 65% evidence | 14.6/20 RS sector 16.2% · RS bench 16.3% · 1Y 36.3%3 of 12 weeks ahead 70% evidence |
| Exact sum: 13.9 + 9.1 + 6 + 14.6 = 43.6 · Decision use: Price leads the evidence: RS versus the benchmark is 16.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13Edgewell Personal Care CompanyEPC | 43.0/100Mixed-negative evidence65% evidence | BREAKING OUT | 9.1/35 Revenue 0.4% · PAT -139.1% · OPM change -6 pp 83% evidence | 8.3/25 ROCE 0.6% · OPM 3.5% 76% evidence | 9.1/20 P/E 38.4× · PEG — 15% evidence | 16.5/20 RS sector 21.1% · RS bench 20.9% · 1Y 29.5%7 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 8.3 + 9.1 + 16.5 = 43 · Decision use: Price leads the evidence: RS versus the benchmark is 20.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 14Nu Skin Enterprises, Inc.NUS | 39.4/100Thin evidence · provisional58% evidence | BASING | 18.2/35 Revenue -14.2% · PAT — · OPM change 4 pp 62% evidence | 6.2/25 ROCE 0.4% · OPM 1.3% 76% evidence | 11.5/20 P/E 6.6× · PEG — 15% evidence | 3.5/20 RS sector -44.5% · RS bench -45.4% · 1Y -40.3%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18.2 + 6.2 + 11.5 + 3.5 = 39.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15The Honest Company, Inc.HNST | 36.8/100Thin evidence · provisional58% evidence | FADING | 9.0/35 Revenue -9.5% · PAT — · OPM change -3.4 pp 62% evidence | 4.7/25 ROCE -0.4% · OPM -0.8% 76% evidence | 9.0/20 P/E 61.3× · PEG — 15% evidence | 14.1/20 RS sector 8.6% · RS bench 8.3% · 1Y -1.3%8 of 12 weeks ahead 70% evidence |
| Exact sum: 9 + 4.7 + 9 + 14.1 = 36.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16The Estée Lauder Companies Inc.EL | 34.1/100Adverse evidence64% evidence | ASLEEP | 14.7/35 Revenue 0.3% · PAT — · OPM change -1.9 pp 62% evidence | 9.4/25 ROCE 1.7% · OPM 6.7% 76% evidence | 8.7/20 P/E 178× · PEG — 15% evidence | 1.3/20 RS sector -14.8% · RS bench -15.1% · 1Y -4.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 9.4 + 8.7 + 1.3 = 34.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17e.l.f. Beauty, Inc.ELF | 31.6/100Adverse evidence81% evidence | BREAKING OUT | 11.5/35 Revenue 24.7% · PAT -76.8% · OPM change -24.5 pp 83% evidence | 6.9/25 ROCE -3.2% · OPM -11.2% 76% evidence | 3.8/20 P/E 137.8× · PEG 5.38 65% evidence | 9.4/20 RS sector -7.5% · RS bench -9.6% · 1Y -13.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 6.9 + 3.8 + 9.4 = 31.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Coty Inc.COTY | 29.7/100Adverse evidence64% evidence | TURNING | 10.3/35 Revenue -3.6% · PAT — · OPM change -7.4 pp 62% evidence | 4.1/25 ROCE -4.4% · OPM -29% 76% evidence | 8.5/20 P/E 20311× · PEG — 15% evidence | 6.8/20 RS sector -11.9% · RS bench -13.5% · 1Y -38.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 10.3 + 4.1 + 8.5 + 6.8 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Oddity Tech Ltd.ODD | 26.0/100Adverse evidence75% evidence | ASLEEP | 9.2/35 Revenue 5.1% · PAT -50.9% · OPM change -28.8 pp 83% evidence | 5.4/25 ROCE -3.9% · OPM -12.9% 76% evidence | 8.4/20 P/E 16.9× · PEG 2.29 65% evidence | 3.0/20 RS sector -55.1% · RS bench -56.8% · 1Y -73.7%2 of 12 weeks ahead 70% evidence |
| Exact sum: 9.2 + 5.4 + 8.4 + 3 = 26 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Unilever PLCUL | 48.4/100Thin evidence · provisional43% evidence | TURNING | 18.2/35 Revenue — · PAT — · OPM change — 12% evidence | 14.3/25 ROCE 4.9% · OPM — 61% evidence | 11.0/20 P/E 12.4× · PEG — 15% evidence | 4.9/20 RS sector -11.1% · RS bench -11.6% · 1Y -6.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 14.3 + 11 + 4.9 = 48.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Acme United Corporation's stock price today?
Acme United Corporation trades at $55.8, +38.9% over the past year. The company is valued at $0.0 B. The stock sits at 94% of its 52-week range of $37–$57, +29.4% versus its 200-day average. Against the S&P 500 it has been ahead on a trailing-13-week view for 3 weeks. — as of 5 August 2026.
What were Acme United Corporation's latest quarterly results?
Acme United Corporation reported revenue of $0.1 B and net profit of $0.0 B for the Mar 26 quarter. Earnings per share were $0.24. The operating margin was 0.0%, 0.0 pp higher than a year earlier. — as of 5 August 2026.
What is Acme United Corporation's revenue?
Acme United Corporation reported revenue of $0.1 B in the Mar 26 quarter, +0.0% year on year. For the full FY25 fiscal year, revenue was $0.2 B (+5.3%). Over the last 4 years revenue compounded at 2.7% a year. — as of 5 August 2026.
What is Acme United Corporation's profit?
Acme United Corporation earned $0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. The operating margin ran 0.0% in the latest quarter. — as of 5 August 2026.
What is Acme United Corporation's market cap?
Acme United Corporation's market capitalisation is $0.0 B at a stock price of $55.8. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Acme United Corporation's P/E ratio?
Acme United Corporation trades at a P/E of 23.4×, at the 96th percentile of its own 1-year range, against a long-run median of 17.4×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Acme United Corporation pay a dividend?
Yes — Acme United Corporation declared $0.16 per share for Mar 26, and $0.64 per share across the last four reported quarters. The latest quarter is up 6.7% on the same quarter a year earlier. — as of 5 August 2026.
What is Acme United Corporation's dividend per share?
Acme United Corporation's most recently declared dividend is $0.16 per share for Mar 26, giving $0.64 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Acme United Corporation's dividend yield?
Acme United Corporation's trailing dividend yield is 1.15%: $0.64 declared per share across the last four reported quarters, against a share price of $55.8. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is Acme United Corporation overvalued?
On its own history, Acme United Corporation looks expensive against its own history: its P/E of 23.4× sits at the 96th percentile of its 1-year range (long-run median 17.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
How is Acme United Corporation performing?
Acme United Corporation's latest readings are below. Against the S&P 500 it has been ahead on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Acme United Corporation in?
Deteriorating — revenue and EPS growth are shrinking (revenue growth −4.8% latest against +16.7% at its 12-quarter best), ROCE holding at 6.2%. The read comes from the last 12 quarters of growth (revenue growth −4.8% latest, eps growth −5.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Acme United Corporation beating the market?
On recent form, yes — Acme United Corporation has been ahead of the S&P 500 on a trailing-13-week view for 3 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.1 years the stock moved +30% against the S&P 500's +24% — ahead of the index over the full window. — as of 5 August 2026.
Will Acme United Corporation's stock price go up?
This page publishes no price forecast for Acme United Corporation. What it measures instead: the stock price is $55.8. Its P/E of 23.4× sits at the 96th percentile of its own 1-year range. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Acme United Corporation?
Somewhat — short interest is 3.2% of Acme United Corporation's tradable float, about 5.3 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Acme United Corporation have too much debt?
It is moderate — Acme United Corporation's debt-to-equity is 0.32. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Acme United Corporation's capex?
Acme United Corporation spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Acme United Corporation's cash flow?
Acme United Corporation generated $0.0 B of operating cash flow in FY25 and $0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Acme United Corporation's profit real cash?
Yes — over the last 3 fiscal years, 150% of Acme United Corporation's reported profit arrived as operating cash. In FY25, operating cash was $0.0 B against reported profit of $0.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Acme United Corporation?
On the balance sheet, the Z-score reads 3.70 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Acme United Corporation in its business cycle?
Acme United Corporation's FY25 operating margin was 5.0%, against a 5-year band of 5.0%–5.6%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 0.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Acme United Corporation story?
The sharpest disagreement: the price moved +38.9% in a year while annual EPS moved +1.6% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Acme United Corporation a stock worth studying right now?
This is not investment advice. The machine read: Acme United Corporation's price has outrun its earnings. +38.9% in a year against EPS +1.6% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.